bluebird bio, Inc. (0HOH.L)

3,2262 +0,1602 (+5,23%) Alla chiusura: 07:12PM BST

bluebird bio, Inc.

60 Binney Street
Cambridge, MA 02142
United States
339 499 9300
https://www.bluebirdbio.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 518

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Andrew Obenshain	Pres, CEO & Director	842,85k	N/D	1975
Mr. Thomas J. Klima	Chief Commercial Officer & COO	509,7k	N/D	1972
Mr. Christopher Krawtschuk CPA	CFO, Principal Accounting Officer & Treasurer	N/D	N/D	1974
Mr. Joseph D. Vittiglio Esq., J.D.	Chief Bus. & Legal Officer	N/D	N/D	1972
Jess Rowlands	Head of Corp. Communications	N/D	N/D	N/D
Ms. Andrea Walton	Chief People Officer	N/D	N/D	N/D
Ms. Melissa Bonner	Sr. VP of Research	N/D	N/D	N/D
Mr. Richard Colvin M.D., Ph.D.	Chief Medical Officer	N/D	N/D	N/D
Mr. Kasra Kasraian	Sr. VP of Technical Devel. & Operations	N/D	N/D	N/D
Mr. Scott Shoemaker	Sr. VP of Quality	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di bluebird bio, Inc. al 1 febbraio 2023 è 6. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 5; diritti degli azionisti: 5; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.